Literature DB >> 20185054

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Barbara J Drew, Michael J Ackerman, Marjorie Funk, W Brian Gibler, Paul Kligfield, Venu Menon, George J Philippides, Dan M Roden, Wojciech Zareba.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20185054      PMCID： PMC3057430          DOI： 10.1016/j.jacc.2010.01.001

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  114 in total

Review 1.  How to correct the QT interval for the effects of heart rate in clinical studies.

Authors:  Patrick Davey
Journal:  J Pharmacol Toxicol Methods       Date:  2002 Jul-Aug       Impact factor: 1.950

2.  Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one.

Authors:  Sami Viskin; Uri Rosovski; Andrew J Sands; Edmond Chen; Peter M Kistler; Jonathan M Kalman; Laura Rodriguez Chavez; Pedro Iturralde Torres; Fernando E S Cruz F; Osmar A Centurión; Akira Fujiki; Philippe Maury; Xiaomin Chen; Andrew D Krahn; Franz Roithinger; Li Zhang; G Michael Vincent; David Zeltser
Journal:  Heart Rhythm       Date:  2005-06       Impact factor: 6.343

Review 3.  Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.

Authors:  Luc M Hondeghem
Journal:  J Cardiovasc Electrophysiol       Date:  2006-03

Review 4.  Clinical safety profile of sotalol in patients with arrhythmias.

Authors:  L F Soyka; C Wirtz; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

5.  Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.

Authors:  Henriette Sloth Pedersen; Hanne Elming; Marie Seibaek; Hans Burchardt; Bente Brendorp; Christian Torp-Pedersen; Lars Køber
Journal:  Am J Cardiol       Date:  2007-06-27       Impact factor: 2.778

Review 6.  Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.

Authors:  D M Roden
Journal:  Eur Heart J       Date:  1993-11       Impact factor: 29.983

7.  Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone.

Authors:  J W Mason; L M Hondeghem; B G Katzung
Journal:  Circ Res       Date:  1984-09       Impact factor: 17.367

Review 8.  What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers.

Authors:  Sergio L Pinski; Luis E Eguía; Richard G Trohman
Journal:  Pacing Clin Electrophysiol       Date:  2002-11       Impact factor: 1.976

9.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

Review 10.  QTc interval in the assessment of cardiac risk.

Authors:  Hanne Elming; Bente Brendorp; Lars Køber; Najia Sahebzadah; Christian Torp-Petersen
Journal:  Card Electrophysiol Rev       Date:  2002-09
View more
  100 in total

1.  Chloroquine-induced QTc prolongation in COVID-19 patients.

Authors:  M P H van den Broek; J E Möhlmann; B G S Abeln; M Liebregts; V F van Dijk; E M W van de Garde
Journal:  Neth Heart J       Date:  2020-04-29       Impact factor: 2.380

Review 2.  Methadone, QTc prolongation and torsades de pointes: Current concepts, management and a hidden twist in the tale?

Authors:  Sobia Mujtaba; Jorge Romero; Cynthia C Taub
Journal:  J Cardiovasc Dis Res       Date:  2013-11-16

3.  The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.

Authors:  Matthew S Duprey; Nada Al-Qadheeb; Russel Roberts; Yoanna Skrobik; Greg Schumaker; John W Devlin
Journal:  Intensive Care Med       Date:  2016-09-16       Impact factor: 17.440

4.  A 26-year-old woman with recurrent loss of consciousness.

Authors:  Mark R Benson; Vikas Kotagal; Hakan Oral
Journal:  J Gen Intern Med       Date:  2011-07-08       Impact factor: 5.128

5.  Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes.

Authors:  Atsushi Sorita; J Martijn Bos; Bruce W Morlan; Robert F Tarrell; Michael J Ackerman; Pedro J Caraballo
Journal:  J Am Med Inform Assoc       Date:  2014-10-16       Impact factor: 4.497

Review 6.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

7.  Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.

Authors:  John D Zeuli; John W Wilson; Lynn L Estes
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

8.  Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.

Authors:  James E Tisdale; Heather A Jaynes; Joanna R Kingery; Brian R Overholser; Noha A Mourad; Tate N Trujillo; Richard J Kovacs
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-05-06

9.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

Review 10.  Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2010-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.